Clot Management Devices Market Report Scope and Overview:

The Clot Management Devices Market was valued at USD 1.91 Billion in 2025 and is projected to reach USD 3.50 Billion by 2035, registering a CAGR of 6.24% from 2026 to 2035.

The Clot Management Devices Market is steadily reshaping the treatment of stroke, pulmonary embolism, deep vein thrombosis and peripheral arterial occlusion by moving care from systemic drugs and open surgery toward minimally invasive, catheter-based clot removal. The market is characterized by rising adoption of large-bore aspiration and stent-retriever thrombectomy for acute ischemic stroke, growing use of mechanical thrombectomy for pulmonary embolism and venous thromboembolism, and expanding evidence that has widened stroke treatment windows and eligible patient groups. Significant growth is being witnessed in neurovascular and percutaneous mechanical thrombectomy platforms, considering that hospitals, stroke centres and ambulatory surgical centres continue investing in devices that restore blood flow faster and reduce bleeding risk compared with thrombolytic drugs.

Stryker completed its acquisition of Inari Medical in February 2025, bringing the FlowTriever and ClotTriever venous thrombectomy systems together with its neurovascular franchise and reflecting the industry's broader shift toward consolidated, full-spectrum clot management portfolios.

Clot Management Devices Market Trends

• Rising use of large-bore and super-bore aspiration catheters continues improving first-pass clot removal in stroke.

• Growing adoption of computer-assisted vacuum thrombectomy continues standardizing aspiration performance.

• Expanding mechanical thrombectomy for pulmonary embolism and DVT continues reducing reliance on thrombolytic drugs.

• Increasing consolidation among major device makers continues reshaping portfolios across neuro, venous and peripheral care.

• Rising shift of peripheral procedures to ambulatory surgical centres continues changing procedure economics.

U.S. Clot Management Devices Market Outlook

The U.S. Clot Management Devices Market was valued at approximately USD 712.84 Million in 2025 and is projected to reach approximately USD 1,252.71 Million by 2035, registering a CAGR of approximately 5.8% from 2026 to 2035.

Demand across the United States continued to be shaped by the country's high incidence of ischemic stroke and venous thromboembolism, established Medicare reimbursement for mechanical thrombectomy, and a dense network of comprehensive and thrombectomy-capable stroke centres. Rising use of mechanical thrombectomy for pulmonary embolism and deep vein thrombosis, along with continued growth of neurovascular procedures, continued reinforcing the country's position as the largest national market. Rapid growth of cardiology- and vascular-led ambulatory surgical centres added further layers of sustained domestic demand, while rural access gaps continue driving investment in hub-and-spoke telestroke networks that expand the treated patient pool.

The U.S. FDA's Quality Management System Regulation, which aligns device quality requirements with ISO 13485, took effect in February 2026, raising documentation and supplier-control requirements for American manufacturers of thrombectomy catheters, retrievers and vena cava filters.

Clot Management Devices Market Segment Analysis

• By Product, Neurovascular Embolectomy/Thrombectomy Devices segment dominated the Clot Management Devices Market in 2025 with 35% share; Mechanical/Percutaneous Thrombectomy Devices segment is the fastest growing segment with a CAGR of approximately 8.1%.

• By End User, Hospitals segment dominated the Clot Management Devices Market in 2025 with 65% share; Ambulatory Surgical Centers (ASCs) segment is the fastest growing segment with a CAGR of approximately 8.4%.

By Product: Neurovascular Thrombectomy Devices Lead, Mechanical/Percutaneous Thrombectomy Devices Grow Fastest

The Neurovascular Embolectomy/Thrombectomy Devices segment dominated the Clot Management Devices Market in 2025, driven by strong clinical evidence supporting mechanical thrombectomy for large vessel occlusion stroke, including trials that extended treatment windows up to 24 hours and supported treatment of large-core infarcts. Stent retrievers and aspiration catheters are now standard care in comprehensive stroke centres, and each procedure uses several high-value devices. Continued improvement in first-pass recanalization rates and growth in stroke centre networks reinforced this segment's position as the largest contributor to total market revenue throughout the base year.

The Mechanical/Percutaneous Thrombectomy Devices segment is the fastest growing in the Clot Management Devices Market owing to rising use of catheter-based clot removal for pulmonary embolism, deep vein thrombosis and peripheral arterial occlusion. Large-bore aspiration and mechanical extraction systems allow physicians to remove clot without thrombolytic drugs, reducing bleeding risk and intensive care stays. Rising clinical evidence, new FDA clearances and the entry of major device makers through acquisitions are accelerating this segment's growth trajectory across interventional radiology, cardiology and vascular surgery. Growing use of computer-assisted aspiration further supports adoption.

By End User: Hospitals Dominate, Ambulatory Surgical Centers Grow Fastest

The Hospitals segment dominated the Clot Management Devices Market because hospitals operate the stroke teams, catheterization laboratories, biplane angiography suites and intensive care capacity needed for emergency thrombectomy and pulmonary embolism response. Acute ischemic stroke and high-risk pulmonary embolism require around-the-clock specialist staffing that only hospitals can provide. Continued investment in comprehensive stroke centre certification and pulmonary embolism response teams reinforced this segment's dominant contribution to total market revenue throughout the base year. Growing hospital procurement of full-portfolio device contracts further reinforced demand.

The Ambulatory Surgical Centers (ASCs) segment is the fastest growing as elective peripheral and venous thrombectomy procedures move out of hospitals into lower-cost outpatient settings. Medicare payment differences favouring ASCs, radial-access techniques and same-day discharge protocols continue improving outpatient procedure economics. Rising numbers of cardiology- and vascular-led ASCs and office-based labs continue attracting a broadening base of physicians toward outpatient clot management. Growing payer support for site-of-care shifts continues accelerating ASC adoption.

Regional Analysis

North America Clot Management Devices Market Insights

North America dominated the Clot Management Devices Market with the largest revenue share of approximately 42.8% in 2025. A high burden of stroke and venous thromboembolism, strong reimbursement for thrombectomy, an extensive network of certified stroke centres and the headquarters of leading device manufacturers continued reinforcing this dominant regional position. Early access to new aspiration catheters, stent retrievers and venous thrombectomy systems through the FDA 510(k) pathway kept the region ahead of most others in technology adoption. Growing hospital investment in pulmonary embolism response teams further reinforced this region's leadership position.

The United States accounted for the substantial majority of regional revenue, anchored by high procedure volumes, Medicare reimbursement and rapid growth of outpatient vascular care. Canada added further demand through its national stroke care networks, although capacity limits slow wider access, and that combined strength kept the region the largest addressable market for clot management device vendors through the forecast period. Continued expansion of telestroke networks into rural areas reinforced sustained procedure growth.

Europe Clot Management Devices Market Insights

Europe held a meaningful share of global revenue, supported by well-established stroke care pathways, public healthcare funding for thrombectomy and strong clinical research activity across the region's major economies. National stroke programmes continued expanding the number of thrombectomy-capable centres, although access still varies widely between countries and rural areas. Implementation of the EU Medical Device Regulation continued shaping product approval timelines and recertification requirements for clot management devices. Growing adoption of mechanical thrombectomy for pulmonary embolism further reinforced regional demand.

Germany continued to lead demand at roughly 24.90% of European revenue, supported by its DRG reimbursement for thrombectomy, dense hospital network and high procedure volumes. The UK, France, Italy and Spain contributed substantial additional demand through expanding stroke centre networks and national health service funding, and continued European investment in stroke and venous care should keep regional demand for clot management devices climbing through the forecast period. Additional demand from the Netherlands, Switzerland and the Nordic countries reinforced broader regional market strength.

Asia Pacific Clot Management Devices Market Insights

Asia Pacific is advancing at the fastest pace, growing at a CAGR of approximately 7.3% from 2026 to 2035. This growth is driven by the large and growing stroke burden in China, India and Japan, rapid expansion of comprehensive stroke centres, and rising government and private investment in neurointerventional capacity, with new catheterization labs and trained interventionalists continuing to broaden the region's addressable base well beyond its traditional smaller footprint. Growing reimbursement coverage for thrombectomy in several countries further accelerated adoption.

China held a substantial share of regional revenue, supported by its national stroke centre network, inclusion of thrombectomy in reimbursement catalogues and growing domestic device manufacturing. Japan and India contributed meaningful additional demand, with Japan's aging population and full procedure reimbursement and India's expanding private hospital neurovascular labs both reinforcing the region's position as the fastest-growing market tracked in this report. South Korea, Australia and Southeast Asian countries contributed smaller but steadily growing regional demand throughout the period.

MEA and Latin America Clot Management Devices Market Insights

The Middle East and Africa and Latin America both showed steady growth, driven by rising stroke and cardiovascular disease prevalence, expanding hospital infrastructure and growing investment in specialized neurovascular and vascular centres across both areas. As these markets continue building interventional capacity, thrombectomy devices offer an effective way to improve stroke outcomes where access to intensive rehabilitation is limited. Growing private hospital investment and physician training programmes across both regions further reinforced device adoption.

Saudi Arabia led Middle East and Africa demand, supported by health sector transformation under Vision 2030 and expanding stroke centres in major cities. The UAE and other Gulf states contributed further demand through premium private hospital networks, while access in most of sub-Saharan Africa remains limited to urban centres. In Latin America, Brazil accounted for the largest share of regional revenue, with its growing stroke networks and large hospital base continuing to anchor regional demand for clot management devices. Mexico and Argentina contributed additional demand, though high out-of-pocket costs still limit access.

Market Dynamics

Growth Drivers: Rising Thromboembolic Disease Burden and Shift to Endovascular Therapy

The industry is driven by the rising global burden of ischemic stroke, pulmonary embolism, deep vein thrombosis and peripheral arterial disease, an aging population with higher clotting risk, and clinical evidence that continues expanding the patients eligible for mechanical thrombectomy. As clinicians continue favouring minimally invasive, catheter-based clot removal over open surgery and systemic thrombolysis, demand for stent retrievers, aspiration catheters and venous thrombectomy systems continues rising across hospitals and stroke centres worldwide. Growing stroke centre certification and pulmonary embolism response programmes further reinforce this sustained industry-wide demand driver.

Rising technical capability of thrombectomy platforms continues reinforcing this driver, as larger-bore catheters, hybrid aspiration and stent techniques, computer-assisted vacuum systems and improved trackability raise first-pass success and shorten procedure times. Frequent 510(k) clearances for incremental device upgrades keep new technology reaching clinicians quickly, and that combination of clinical evidence and innovation keeps demand rising at a steady, sustained pace. Expanding physician training and proctoring programmes are further widening the addressable user base.

Restraints: High Procedure Costs and Competition From Anticoagulant Therapy

The high cost of thrombectomy devices, angiography suites and specialist staff continues posing a restraint on faster market-wide expansion, particularly in cost-constrained health systems across Southern Europe, Latin America and Southeast Asia. Many regional hospitals lack biplane angiography equipment and default to lower-cost thrombolytic drugs. Stricter clinical evidence requirements from the FDA and EU MDR also raise development costs and extend time to market for new devices.

Growing use of direct oral anticoagulants for venous thromboembolism continues posing a further restraint on inferior vena cava filters and catheter-directed thrombolysis devices. Safety and retrieval concerns linked to implanted filters keep some clinicians cautious about their use. Variability in reimbursement for venous and peripheral thrombectomy across countries continues prolonging adoption barriers in several regions.

Opportunities: Next-Generation Aspiration Platforms and Emerging Market Stroke Care

Rising investment in super-bore aspiration catheters, computer-assisted vacuum thrombectomy, medium-vessel occlusion devices and hybrid aspiration-pharmacologic catheters represents a significant opportunity, as physicians seek faster and more complete clot removal with fewer passes. Vendors positioned early in integrated neuro, venous and peripheral portfolios stand to capture meaningful share as hospitals consolidate purchasing around full-spectrum suppliers. Expanding clinical evidence in pulmonary embolism and distal vessel stroke continues widening this addressable opportunity.

Closing stroke care gaps across emerging markets offers a second substantial opportunity, as rising stroke prevalence, stroke centre construction and interventionalist training continue creating fresh demand for thrombectomy devices. Vendors with cost-effective device portfolios and strong training support stand to capture meaningful share as developing economies expand neurovascular capacity. Continued growth of private hospital networks across India, China, the Middle East and Latin America is further accelerating local technology adoption.

Recent Developments:

• July 2026: AngioDynamics, Inc. reported continued growth of its thrombus management platform, led by the AlphaVac and AngioVac systems, in its fiscal year 2026 fourth-quarter update, highlighting its focus on venous and pulmonary embolism clot removal.

• April 2026: Rapid Medical received U.S. FDA 510(k) clearance for TIGERTRIEVER 25, an adjustable stent retriever designed to treat large clot burden in proximal vessels during stroke thrombectomy.

• March 2026: Perfuze received U.S. FDA 510(k) clearance for Millipede88, a super-bore aspiration catheter cleared for standalone direct aspiration thrombectomy in acute ischemic stroke.

• January 2026: Boston Scientific Corporation announced a definitive agreement to acquire Penumbra, Inc. for approximately USD 14.5 billion, expanding its mechanical thrombectomy and neurovascular intervention portfolio.

• January 2026: Verge Medical received U.S. FDA 510(k) clearance for its RoVo Mechanical Thrombectomy System for peripheral clot removal.

• July 2025: Teleflex Incorporated completed its acquisition of BIOTRONIK's vascular intervention business for approximately EUR 760 million, strengthening its catheter-based vascular portfolio in Europe.

Clot Management Devices Market key players are:

• Boston Scientific Corporation

• Penumbra, Inc.

• Stryker Corporation (Inari Medical)

• Medtronic plc

• Johnson & Johnson MedTech (Cerenovus)

• Abbott Laboratories

• Terumo Corporation

• Teleflex Incorporated

• AngioDynamics, Inc.

• Edwards Lifesciences Corporation

• BD (Becton, Dickinson and Company)

• Cook Group Incorporated

• Merit Medical Systems, Inc.

• LeMaitre Vascular, Inc.

• Rapid Medical

• Imperative Care, Inc.

• Perfuze

• iVascular S.L.U.

• Argon Medical Devices, Inc.

Clot Management Devices Market Report Scope: